Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Non-Current Debt of $2.6 billion for Q1 2026, up 19.4% year-over-year from $2.2 billion in Q1 2025, and little changed quarter-over-quarter from $2.6 billion in Q4 2025.
Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Non-Current Debt history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.
- In Q1 2026, Non-Current Debt rose 19.4% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 19.4% YoY), while the FY2025 annual figure was $2.6 billion, up 7.79% from the prior year.
- Non-Current Debt for Q1 2026 stood at $2.6 billion, roughly flat from $2.6 billion in the prior quarter.
- The five-year high for Non-Current Debt was $2.7 billion in Q1 2022, with the low at $38.9 million in Q2 2022.
- The 5-year median for Non-Current Debt is $2.4 billion (2023), against an average of $2.2 billion.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 7157.14% in 2022, then retreated 15.66% in 2024.
- Amneal Pharmaceuticals' Non-Current Debt stood at $2.6 billion in 2022, then declined by 6.63% to $2.4 billion in 2023, then fell by 1.41% to $2.4 billion in 2024, then increased by 7.79% to $2.6 billion in 2025, then fell by 0.0% to $2.6 billion in 2026.
- Business Quant data shows AMRX's Non-Current Debt at $2.6 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 2.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.57 Bn |
| Mar 31, 2026 | 2.57 Bn |
| Dec 31, 2025 | 2.57 Bn |
| Sep 30, 2025 | 2.57 Bn |
| Jun 30, 2025 | 2.18 Bn |
| Mar 31, 2025 | 2.15 Bn |
| Dec 31, 2024 | 2.39 Bn |
| Sep 30, 2024 | 2.17 Bn |
| Jun 30, 2024 | 2.40 Bn |
| Mar 31, 2024 | 2.41 Bn |
| Dec 31, 2023 | 2.42 Bn |
| Sep 30, 2023 | 2.57 Bn |
| Jun 30, 2023 | 2.55 Bn |
| Mar 31, 2023 | 2.56 Bn |
| Dec 31, 2022 | 2.59 Bn |
| Sep 30, 2022 | 39.28 Mn |
| Jun 30, 2022 | 38.86 Mn |
| Mar 31, 2022 | 2.67 Bn |
| Dec 31, 2021 | 2.68 Bn |
| Sep 30, 2021 | 37.63 Mn |